"HIV-1" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte.
MeSH Number(s)
B04.820.650.589.650.350.400
B04.909.777.731.589.650.350.400
Concept/Terms
HIV-1- HIV-1
- Immunodeficiency Virus Type 1, Human
- Human Immunodeficiency Virus Type 1
- HIV-I
- Human immunodeficiency virus 1
Below are MeSH descriptors whose meaning is more general than "HIV-1".
Below are MeSH descriptors whose meaning is more specific than "HIV-1".
This graph shows the total number of publications written about "HIV-1" by people in Harvard Catalyst Profiles by year, and whether "HIV-1" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1992 | 78 | 6 | 84 |
| 1993 | 72 | 5 | 77 |
| 1994 | 84 | 8 | 92 |
| 1995 | 78 | 7 | 85 |
| 1996 | 102 | 4 | 106 |
| 1997 | 112 | 10 | 122 |
| 1998 | 130 | 9 | 139 |
| 1999 | 131 | 9 | 140 |
| 2000 | 131 | 22 | 153 |
| 2001 | 104 | 32 | 136 |
| 2002 | 105 | 19 | 124 |
| 2003 | 106 | 23 | 129 |
| 2004 | 108 | 19 | 127 |
| 2005 | 124 | 19 | 143 |
| 2006 | 130 | 31 | 161 |
| 2007 | 132 | 23 | 155 |
| 2008 | 124 | 34 | 158 |
| 2009 | 140 | 34 | 174 |
| 2010 | 154 | 32 | 186 |
| 2011 | 139 | 41 | 180 |
| 2012 | 178 | 43 | 221 |
| 2013 | 165 | 33 | 198 |
| 2014 | 156 | 34 | 190 |
| 2015 | 133 | 35 | 168 |
| 2016 | 118 | 24 | 142 |
| 2017 | 97 | 41 | 138 |
| 2018 | 108 | 29 | 137 |
| 2019 | 88 | 42 | 130 |
| 2020 | 92 | 42 | 134 |
| 2021 | 93 | 21 | 114 |
| 2022 | 16 | 4 | 20 |
Below are the most recent publications written about "HIV-1" by people in Profiles.
-
Effects of Sex, Existing Antibodies, and HIV-1-Related and Other Baseline Factors on Antibody Responses to Quadrivalent HPV Vaccine in Persons With HIV. J Acquir Immune Defic Syndr. 2022 04 01; 89(4):414-422.
-
Infusion Reactions After Receiving the Broadly Neutralizing Antibody VRC01 or Placebo to Reduce HIV-1 Acquisition: Results From the Phase 2b Antibody-Mediated Prevention Randomized Trials. J Acquir Immune Defic Syndr. 2022 04 01; 89(4):405-413.
-
Point-of-care semi-quantitative test for adherence to tenofovir alafenamide or tenofovir disoproxil fumarate. J Antimicrob Chemother. 2022 Mar 31; 77(4):996-999.
-
Hypermethylation at the CXCR5 gene locus limits trafficking potential of CD8+ T cells into B-cell follicles during HIV-1 infection. Blood Adv. 2022 Mar 22; 6(6):1904-1916.
-
mRNA-encoded HIV-1 Env trimer ferritin nanoparticles induce monoclonal antibodies that neutralize heterologous HIV-1 isolates in mice. Cell Rep. 2022 03 15; 38(11):110514.
-
Pre-infection plasma cytokines and chemokines as predictors of HIV disease progression. Sci Rep. 2022 02 14; 12(1):2437.
-
Spatial and Genomic Correlates of HIV-1 Integration Site Targeting. Cells. 2022 02 14; 11(4).
-
Natural Killer Cell Receptors and Ligands Are Associated With Markers of HIV-1 Persistence in Chronically Infected ART Suppressed Patients. Front Cell Infect Microbiol. 2022; 12:757846.
-
Evaluation of Diagnostic Microbiology Capacity and Barriers in Testing for HIV and TB at Peripheral Hospital-Based Laboratories in Oyo-State, Nigeria. Microbiol Spectr. 2022 02 23; 10(1):e0045921.
-
Evaluation of HIV-1 reservoir size and broadly neutralizing antibody susceptibility in acute antiretroviral therapy-treated individuals. AIDS. 2022 02 01; 36(2):205-214.